The changing profile of ankylosing spondylitis in the biologic era

John D. Reveille, Min Jae Lee, Lianne S. Gensler, Michael M. Ward, Mark C. Hwang, Thomas J. Learch, Amirali Tahanan, Laura Diekman, Mohammad H. Rahbar, Mariko L. Ishimori, Michael H. Weisman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objective: To compare disease characteristics, comorbidities, and medication utilization of 1141 patients with ankylosing spondylitis (AS) with short (< 20 years) and long (≥ 20 years) disease duration enrolled in the Prospective Study of Outcomes in AS (PSOAS) study over three different periods of time and followed longitudinally. Methods: Study visits were carried out every 6 months examining disease activity (Bath AS Disease Activity Index (BASDAI), C-reactive protein, erythrocyte sedimentation rate), functional impairment, depression, and medication utilization as well as radiographic severity. Groups were compared with regression models using generalized estimating equation, linear, and Poisson regressions after adjusting for sites and for patients withdrawing from the study at less than 2 years follow-up. Results: Overall, AS patients with long disease duration were more likely to be married, white, receiving disability, and to be with higher functional impairment and radiographic severity, more uveitis, diabetes, hypertension, cardiovascular disease, and osteoporosis, and with less nonsteroidal anti-inflammatory drug (NSAID) and more opioid use than those with short disease duration. Current smoking decreased between 2002 and 2019 regardless of disease duration. Lower baseline NSAID and methotrexate/sulfasalazine use and higher TNF inhibitor usage were seen only in those with shorter disease duration, though NSAID use and functional impairment decreased over time in both groups. Disease activity, depression scores, and NSAID use decreased and anti-TNF use increased in those followed > 8 years. Conclusions: Patients with AS enrolling in this multicenter longitudinal cohort have different disease profiles and medication utilization over time, perhaps reflecting innovations in treatment and increasing disease awareness.Key Points• The use of NSAIDs, nonbiologic DMARDs, and prednisone has decreased over the past 16 years in patients with AS.• The use of anti-TNF agents has dramatically increased.• In treated patients, disease activity, depression scores, and functional impairment have decreased over time.

Original languageEnglish (US)
Pages (from-to)2641-2651
Number of pages11
JournalClinical Rheumatology
Issue number9
StatePublished - Sep 1 2020


  • Ankylosing spondylitis
  • Clinical features
  • Comorbidities
  • Disease progression
  • Drug therapy

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'The changing profile of ankylosing spondylitis in the biologic era'. Together they form a unique fingerprint.

Cite this